Graft-versus-host disease after donor leukocyte infusions: presentation and management
Graft-versus-host disease after donor leukocyte infusions: presentation and management
复制标题
DOI：
10.1016/j.beha.2008.02.007
复制
发表时间：
2008-06-01
影响因子：
2.1
通讯作者：
Porter, David L.
中科院分区：
文献类型：
--
作者：
Frey, Noelle V.;Porter, David L.
供体白细胞输注（DLI）用于清髓性和非清髓性干细胞移植后，以治疗和预防复发，建立完全供体嵌合体，并治疗和预防感染。DLI的主要治疗相关并发症是移植物抗宿主病（GVHD）。DLI后GVHD的表现和治疗与干细胞移植后的表现和治疗相似，但有一些明显的例外。虽然GVHD和移植物抗肿瘤（GVT）效应在DLI后高度相关，但一些患者在没有GVHD的情况下缓解。确定肿瘤特异性靶抗原和GVT效应细胞的研究，以及供体T细胞操作和DLI剂量和时间表优化的策略，可能最终导致将GVHD与GVT活性分离的一致能力，DLI的安全性和特异性的改善，以及供体T细胞的抗肿瘤活性的增强。
Donor leukocyte infusion (DLI) is used after both myeloablative and non-myeloablative stem-cell transplantation to treat and prevent relapse, to establish full donor chimerism, and to treat and prevent infections. The major treatment-related complication of DLI is graft-versus-host disease (GVHD). The presentation and treatment of GVHD after DLI is similar to its presentation and treatment after stem-cell transplantation, with some notable exceptions. While GVHD and graft-versus-tumor (GVT) effects are highly correlated after DLI, some patients experience remission without GVHD. Studies to define tumor-specific target antigens and GVT effector cells, as well as strategies of donor T-cell manipulation and optimization of DLI dose and schedule, may ultimately lead to the consistent ability to separate GVHD from GVT activity, improvement in the safety and specificity of DLI, and enhancement of the anti-tumor activity of donor T cells.